AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02202096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient hotline: 24 hour follow-up following call to Ask My Nurse number
Description: Follow-up will occur within 24 hours of calling the Ask My Nurse number. Patients with emergent problems will be seen immediately by the surgical oncology team if available or the on call surgery team. Patients with non-urgent matters will be called by a member of the surgical oncology team. Arrangements will be made to see the patient in clinic or the ER within the next 8-16 hours depending upon severity and time of day.
Study NCT03060603 — intervention group
Intervention type: DRUG
Intervention: Erythropoietin
Description: Recombinant Human Erythropoietin, three times in a week, until the correction of anemia, approximately two months.
Study NCT01963299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 ml Ropivacaine 10% + physiological saline
Study NCT01963299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 ml Ropivacaine 10% + Clonidine 1 µg/kg
Study NCT03050359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets
Study NCT04159675 — intervention group
Intervention type: BIOLOGICAL
Intervention: osteoblast biology study
Description: Describe the in-vitro action of burosumab and vitamin D on human osteoblastogenesis from osteoblasts from patients with craniosynostosis due to HR
Study NCT04691375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY314
Description: Dose of PY314 as a single agent given in a standard 3+3 design.
Study NCT02688439 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sciatic Nerve block
Study NCT03050359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole capsules
Study NCT03050359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438 Placebo
Description: TAK-438 placebo-matching tablets.
Study NCT03050359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole Placebo
Description: Lansoprazole placebo-matching capsules
Study NCT03050359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth-Containing Quadruple Therapy
Description: 1 g Amoxicillin, 500 mg clarithromycin and 600 mg bismuth potassium citrate/bismuth tripotassium dicitrate, twice daily (BID).
Study NCT02688439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leg raised 30°
Study NCT02688439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distal tourniquet placed on the lower part of the leg
Study NCT02688439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leg in a neutral position
Study NCT02688439 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Leg in a neutral position
Study NCT04162834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Papaverine
Description: Immediately after the renal artery declamping, papaverine 30 mg (1 ample, 1 ml) is mixed with 5 ml of normal saline (total 6 ml) and sprinkled around the renal artery.
Study NCT04162834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Immediately after the renal artery declamping, normal saline 6 ml is sprinkled around the renal artery.
Study NCT05755750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genipin
Description: Intratendinous genipin injection
Study NCT02020161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atra
Study NCT02370355 — intervention group
Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of blood samples
Study NCT02370355 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02020161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Study NCT02020161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT04343079 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET CT
Description: measurement of surgical margins during lumpectomy
Study NCT03342482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-glutamate diet
Description: The dietary intervention consists of a one-month low-glutamate diet, followed by a randomized crossover challenge with MSG and placebo to measure return of symptoms.
Study NCT03342482 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low-glutamate diet
Description: The dietary intervention consists of a one-month low-glutamate diet, followed by a randomized crossover challenge with MSG and placebo to measure return of symptoms.
Study NCT02141646 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: The main goals of motivational interviewing are to engage clients, elicit change talk, and evoke motivation to make positive changes from the client.
Study NCT02141646 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Skills Training
Description: Behavioral Skills Training (BST) is a training package that utilizes instructions, modeling, rehearsal, and feedback in order to teach a new skill.
Study NCT04987060 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intrastromal Fresh Human Lenticule Implantation
Description: The stromal pocket diameter was set 8.0 mm and cap thickness was set to 140 μm from corneal surface and a 2mm superior incision. Hinge position flap was set at 90°, angle 50° and width 4 mm, side cut angle 90°. The pocket was dissected using a blunt spatula washed with normal saline. The lenticule was held with lenticule forceps and gently inserted into the pocket through the 2 mm superior incision. Incision position changed according to the position of the highest K values.
Study NCT00793676 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: spirometry
Study NCT00793676 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood test
Study NCT04048525 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CVVHD
Description: CVVHD will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as dialysate fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed. Isovolemic CRRT will be encouraged during this 72 hours if volume overload status is not present. After 72 hours, CVVHD will be continued and dialysate dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
Study NCT04048525 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CVVH
Description: CVVH will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as reposition fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed adjusting the adequate percentage of prefilter infusion to maintain a theoretical filtration fraction between 18-22%. Isovolemic CRRT will be encouraged if volume overload status is not present. After 72 hours, CVVH will be continued and filtration dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
Study NCT02239770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Film
Description: Nicotine orally dissolving films (ODF) are films containing nicotine (0, 2, or 4 mg). The active pharmaceutical ingredient in Nicotine ODF is nicotine polacrilex (20%, USP). The film used in Nicotine ODF has a muco-adhesive property, i.e. it can adhere to the oral mucosa and allow the drug to be absorbed through oral mucosa. After placement in the oral cavity, nicotine ODF dissolves over a 5-10 minute period.The unit-dose dosage is in the form of 1 in x 1 in square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.
Study NCT02239770 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nicotine Film
Description: Nicotine orally dissolving films (ODF) are films containing nicotine (0, 2, or 4 mg). The active pharmaceutical ingredient in Nicotine ODF is nicotine polacrilex (20%, USP). The film used in Nicotine ODF has a muco-adhesive property, i.e. it can adhere to the oral mucosa and allow the drug to be absorbed through oral mucosa. After placement in the oral cavity, nicotine ODF dissolves over a 5-10 minute period.The unit-dose dosage is in the form of 1 in x 1 in square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.
Study NCT04365439 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood plasma
Description: Convalescent plasma after COVID-19
Study NCT04501198 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: moxibustion combined with characteristic lifestyle intervention of traditional chinese medicine
Description: 1. The moxibustion acupoints will be selected as①zhongwan, guanyuan, shenque, and zusanli;②pishu,shenshu. Acupoints group①will be selected on Monday, Wednesday, and Friday, Acupoints group②will be selected on Tuesday, Thursday, Saturday.Moxibustion treatment will be applied once every day, 6 times per week, for 8 consecutive weeks.~2. Xiusheng decoction, traditional exercises, and modern lifestyle intervention will be combined as the characteristic lifestyle intervention method of TCM to help participants establish healthy living habits. The Xiusheng Decoction should be taken twice a day. Traditional exercises will be taken for 35\~40 minutes everyday, 7 times a week. The intervention of Xiusheng Decoction and traditional exercises will be conducted for 8 weeks. All patients will be instructed to follow a good living habits which will last 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks.
Study NCT04501198 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moxibustion combined with lifestyle intervention.
Description: 1. The moxibustion acupoints will be selected as①zhongwan, guanyuan, shenque, and zusanli;②pishu,shenshu. Acupoints group①will be selected on Monday, Wednesday, and Friday, Acupoints group②will be selected on Tuesday, Thursday, Saturday.Moxibustion treatment will be applied once every day, 6 times per week, for 8 consecutive weeks.~2. All patients will be instructed to follow a good living habits including diet and exercise intervention which will last 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks.
Study NCT04501198 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: lifestyle intervention
Description: All patients will be instructed to follow a good living habits including diet and exercise intervention which will last 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks.
Study NCT02856269 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc gluconate
Description: Participants will take a daily dose of zinc gluconate.
Study NCT04365985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Low dose naltrexone, 4.5 mg by mouth, given from date of admission through time participant is stable for discharge for inpatient participants with mild/moderate COVID-19 infection stages. Naltrexone will continue for 1 month post hospital discharge. Patients progressing to requirement for advanced oxygenation will be reassess when sedation and assigned to Ketamine arm. Naltrexone may be reduced to 1.5 mg/day if interfering with sedation and can be held when sedation and symptoms of withdrawal is an issue..
Study NCT04365985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Low dose ketamine hydrochloride given intravenously at a dosage of 0.15 mg/kg body weight for maximum 20 mg every 6 hours, to inpatient participants with advanced oxygenation requirements from either time of admission or time of progression of mild/moderate disease until time participant is stable for discharge, as a rescue treatment. If patient is transferred from the naltrexone or placebo arm, they will continue to receive naltrexone/placebo. Dosage of ketamine may be increased to 0.3 mg/kg body weight, maximum 30 mg every 6 hours, if participant does not respond at the lower dosage. Ketamine can be reduced back to 0.15 mg/kg at the clinical decision of the investigator and when patient has hypertensive emergency, the dose can be held until hypertensive emergency is controlled.
Study NCT04365985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo, given from date of admission through time participant is stable for discharge for inpatient participants in mild/moderate COVID-19 infection stages. Placebo will continue for 1 month post discharge. Participants progressing to requirement for advanced oxygenation will be reassigned to Ketamine arm.
Study NCT04365985 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo, given from date of admission through time participant is stable for discharge for inpatient participants in mild/moderate COVID-19 infection stages. Placebo will continue for 1 month post discharge. Participants progressing to requirement for advanced oxygenation will be reassigned to Ketamine arm.
Study NCT00575952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV or IP
Study NCT00575952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT00575952 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study NCT00575952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV or IP
Study NCT00575952 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC
Study NCT04068324 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: New Care No Nil Per Os
Description: The product name NoNPO is from South Korean company Well life. It contains carbohydrate and is frequently used in preoperative fasting patients in order to alleviate patients' discomfort resulting from empty stomach and thirst. It is also known to decrease insulin resistant.
Study NCT04200677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monophasic Current (100 Hz) with 1ms pulse width applied to the Tibial Nerve
Description: The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following NMES parameters: (Monophasic Current, 100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s)
Study NCT04200677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biphasic current (100 Hz) with pulse width 0.5ms applied to the Tibial Nerve
Description: The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 100 Hz, pulse duration 0.5 ms, Ton: 6 s, Toff: 18 s)
Study NCT04200677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biphasic current (100 Hz) with 1ms pulse width applied to the Tibial Nerve
Description: The participants will perform 36 contractions evoked by neuromuscular electrical stimulation with the following current parameters: (Biphasic current, 100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s)
Study NCT01170351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine-A
Description: Cyclosprorine-A will be administered to patients in group-B according to a set protocol and the patients will be followed at regular intervals with appropriate checking of clinical and para-clinical data.
Study NCT01170351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine-A
Description: Cyclosprorine-A will be administered to patients in group-B according to a set protocol and the patients will be followed at regular intervals with appropriate checking of clinical and para-clinical data.
Study NCT01734525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Description: Anidulafungin at a dose of 200 mg in the first day and 100 mg daily afterwards
Study NCT03973944 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cardiac resynchronization therapy
Description: Atrio-biventricular pacing to shorten the prolonged PR interval
Study NCT01590836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Administered subcutaneously (s.c., under the skin) once daily (plus insulin aspart as bolus insulin as required).
Study NCT01590836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Single dose administered subcutaneously (s.c., under the skin).
Study NCT04306354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Oxytocin nasal spray 24 UI twice daily as adjunctive treatment to conventional treatment during 10 days of detoxification of crack cocaine
Study NCT04306354 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo nasal spray
Description: Nasal spray with placebo solution (2% odor-generating propolis essence + the same vehicle as intra-nasal oxytocin: 0.05% citric acid, 0.9% sodium chloride, 1% glycerol, 0.54% disodium phosphate, 0.2% methylparaben + propylparaben, 1% sorbitol, 80% water) twice daily as adjunctive treatment to conventional treatment.
Study NCT00565110 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADAPt-C intervention
Description: Experimental Arm patients receive: first-line choice of antidepressant medication management,psychotherapy or both; depression education, and maintenance/relapse prevention counseling based on a stepped care depression treatment algorithm, treatment follow-up and feedback to the oncologist, and systems navigation; a psychiatric consultant who prescribes antidepressant medication for individual patients; and a didactic for oncologists on depression management. Cultural adaptations include: patient choice of first line treatment and degree of family participation in their depression care; PST tailored for literacy and patients with cancer; bilingual, bicultural CDCS; Spanish educational materials.
Study NCT00516386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RhIGF-1
Description: 35-40 mcg/k/dose twice daily SC
Study NCT00711958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX575, solution for injection (s.c.)
Description: 1000, 2000, 4000, 8000 and 10.000 IU of rh erythropoiethin
Study NCT00711958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ERYPO®, Janssen-Cilag, solution for injection (s.c.)
Description: 1000, 2000, 4000, 8000 and 10.000 IU of epoetin alfa
Study NCT00164281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Daily 300 mg isoniazid supplemented with 25 mg pyridoxine for 6 months vs 36 months.
Study NCT04691375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Therapy: PY314 + Pembrolizumab
Description: Dose of PY314 alone and given in combination with pembrolizumab
Study NCT00665834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rosuvastatin
Description: rosuvastatin 20 mg from day 0 to (maximum) day 6
Study NCT00665834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 20 mg from day 0 to (maximum) day 6
Study NCT00665834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin
Description: rosuvastatin 20 mg from discharge until the end of the study
Study NCT00665834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: atorvastatin 80 mg from discharge until the end of the study
Study NCT01942109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Drug will be administered per os. Dose of the agent will be adapted to clinical status of the patient. Equipotential dose for furosemide is torasemide in dose 1:4 of furosemide
Study NCT01942109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torasemide
Description: Drug will be administered per os. Dose of the agent will be adapted to clinical status of the patient. Equipotential dose for furosemide is torasemide in dose 1:4 of furosemide
Study NCT04244734 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care treatment
Description: All evaluations are the same in both groups:~Baseline evaluation~ICU admission (If patient hemodynamically stable initiates physiotherapy treatment within the first 15 days after surgery).~Treatment:A daily session from Monday to Friday of 40 minutes according to patient functional status: Passive or active-assisted or active mobilizations, muscle enhancement, respiratory physiotherapy and inspiratory muscle training at 40% of the PIM value.~2nd evaluation when patient has a RASS -1/0 score: 3rd evaluation when ICU discharge.~Treatment ward: A 60-minute daily session according to patient functional status in the gym (physiotherapy area in hospital): Cycloergometer, muscle enhancement, respiratory physiotherapy and inspiratory muscle training.~4th evaluation when hospital discharge 5th evaluation (1 month after discharge) 6th evaluation (4 months after discharge) 7th evaluation (1 year after surgery)